Fairvalue-Calculator Fairvalue-Calculator
EN DE

Bloomage BioTechnology Corporation (688363) Fair Value & Analysis

Basic Materials · CN · Market cap 17.5B CNY

Price¥35.82
Fair Value¥13.33
Upside-62.8%
Quality95/100
Evidence: High Range ¥11.37 – ¥17.05

Analysis

Bloomage BioTechnology Corporation (688363) currently trades at ¥35.82, while our model-based Fair Value estimate is ¥13.33 — implying the stock looks roughly 62.8% overvalued today. We read business quality at 95/100 (high quality), in the Basic Materials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Bloomage BioTechnology Corporation Limited researchers, develops, produces, and sells bioactive materials. It offers pharmaceutical grade sodium hyaluronate which can be used as an API or excipient for drugs and medical devices in ophthalmic preparations, intra-articular injections, anti-adhesive preparations, and topical preparations for wound healing and soft tissue filler under the Hyature name; and cosmetic grade sodium hyaluronate solutions for cosmetic products, including moisturizing, repairing, delay skin aging, and brightening under the Hybloom, miniHA, microHA, Hyacross, Hyacolor, and cationHA. The company also provides food-grade sodium hyaluronate for use in food/healthy food/dietary supplements under the HAPLEX name, as well as food-grade gamma aminobutyric acid under the Gabarelax name; hyaluronic acid for oral care under the Biomoist name; and animal care products under the HYAPET names. Bloomage BioTechnology Corporation Limited was founded in 2000 and is based in Ji…

Open the full interactive analysis →

Similar stocks

Linde plc (LIN) -56% L'Air Liquide S.A (AIQUY) -66% Air Products and Chemicals, Inc (A1PD34) -86% Intercontinental Exchange, Inc (I1CE34) -80% Wanhua Chemical Group (600309) -8% Asian Paints Limited (ASIANPAINT) -72%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.